Phase 1 Study of ADX-626 in Healthy Participants

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Adult Participants

In brief

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).

Key facts

Study ID

NCT07081503

Run by

ADARx Pharmaceuticals, Inc.

People needed

44

Starts

2025-08-12

Expected to finish

2027-01-22

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

Where it is running

• Richmond Pharmacology — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.